New Trial Explores HMB Supplement as Potential Treatment for Cirrhosis
A dietary supplement typically used for muscle growth and preservation may offer hope to thousands of UK residents suffering from chronic liver disease, specifically cirrhosis. Researchers are initiating a clinical study to assess the supplement’s efficacy in improving patients’ physical function and quality of life.
Background on Cirrhosis in the UK
Cirrhosis, a devastating condition resulting from liver scarring, impacts approximately 60,000 individuals in the United Kingdom each year. Harmful alcohol consumption and fatty liver disease are the primary triggers of this malady. In advanced stages, cirrhosis often necessitates liver transplantation or management through symptom alleviation.
The burden of cirrhosis extends beyond individual suffering, imposing a substantial economic strain on health services. Annually, the NHS shoulders over £17 billion in costs related to cirrhosis, with the condition resulting in more than 75,000 admissions.
Introducing the BOOST Study
The BOOST (Building Opportunities for Outcomes in Cirrhosis Through HMB) study, funded by the Research for Patient Benefit (RfPB) program from the National Institute for Health and Care Research (NIHR), aims to investigate the benefits of HMB (hydroxy-methylbutyrate) in patients with cirrhosis.
This initiative is a collaboration among hepatology experts, immunologists, and dietitians from the University of Plymouth, University of Southampton, and Imperial College London. The Peninsula Clinical Trials Unit (PenCTU) manages the trial, scheduled to conclude in 2027.
Project Scientist: Dr. Ashwin Dhanda
Dr. Ashwin Dhanda, Associate Professor in Hepatology at the University of Plymouth and Consultant in Hepatology at University Hospitals Plymouth NHS Trust, leads the BOOST study. According to Dr. Dhanda, “Cirrhosis severely impairs both physical and mental wellbeing. Although several treatments are under development, no medications currently available directly target this condition. HMB shows promising potential to fill this gap without indicating any adverse side effects.”
The study involves recruiting 124 patients across eight English outpatient clinics, including areas with higher rates of cirrhosis. Researchers will monitor participants’ progress through various assessments, including the Liver Frailty Index, to evaluate changes in liver disease, quality of life, and mental health.
Patient Engagement and Tentative Benefits
Engaging directly with patients diagnosed with liver cirrhosis, project leaders obtained insights into their expectations. One patient highlighted the debilitating nature of this illness: “Living with advanced cirrhosis feels like having no energy or strength. There are no treatments out there to help manage your symptoms. I believe taking care of yourself is crucial, and I think the BOOST trial is testing something simple and safe that may improve the quality of life of people with advanced cirrhosis.”
Future Implications and promise
The results from the BOOST study may pave the way for novel therapies in cirrhosis management. By confirming the safety and efficacy of HMB, the supplementary treatment could significantly enhance patients’ lives, reduce healthcare burdens, and alleviate the anguish of those with severe liver disease.
Call to Action
This groundbreaking trial represents a beacon of hope for the many affected by cirrhosis across the United Kingdom. Stay informed about the progress of the BOOST study as it unfolds. If you or someone you know is impacted by chronic liver disease, participating in or supporting similar research initiatives could be vital in the fight against this condition.
We welcome your thoughts on this remarkable development. Feel free to leave a comment below to share your insights or questions. Don’t forget to subscribe to our newsletter for more updates and subscribe to Archynetys on social media for the latest health news.